Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

Xinlun Tian  
Peking Union Medical College Hospital  
https://orcid.org/0000-0003-4307-6665

Yanli Yang  
Peking Union Medical College Hospital

Lulu Chen  
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

Xin Sui  
Peking Union Medical College Hospital Department of Radiology

Wenshuai Xu  
Peking Union Medical College Hospital

Xue Li  
Peking Union Medical College Hospital

Xiaobel Guo  
Peking Union Medical College Hospital

Lingshan Liu  
Peking Union Medical College Hospital

Yusen Situ  
University of Alberta Faculty of Medicine and Dentistry

Jun Wang  
Peking Union Medical College Hospital

Yang Zhao  
Peking Union Medical College Hospital

Shuzhen Meng  
Peking Union Medical College Hospital

Wei Song  
Chinese Academy of Medical Sciences & Peking Union Medical College Institute of Radiation Medicine

Yonglong Xiao  
Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

Kai-Feng Xu  
xuf@pumch.cn  
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Research

Keywords: autoimmune pulmonary alveolar proteinosis, granulocyte-macrophage colony stimulating factor, inhalation

DOI: https://doi.org/10.21203/rs.3.rs-18107/v2

License: © Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Treatment of autoimmune pulmonary alveolar proteinosis (aPAP) by inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) is considered safe and effective. Evidence of benefit from GM-CSF inhalation for mild to moderate aPAP patients is limited.

**Methods:** In this multicenter, randomized, open-labeled clinical trial, 36 aPAP patients with mild to moderate disease severity were randomized into either the GM-CSF treatment group or control group. Inhaled GM-CSF was prescribed for 6 months, and patients received follow-up for another 18 months without treatment. Physiological features of the patients were analyzed.

**Results:** There were 36 patients (19 in the treatment group, 17 in the control group) included. There were no significant differences in the primary endpoints as measured by the change of alveolar arterial oxygen gradient (A-aDO₂) from the baseline values to the values obtained during treatment or during the following 18-month non-treatment observation period (control group vs. treatment group: 0.51±12.09 mmHg vs. -0.35±13.76 mmHg, p=0.848 (3 month); 1.85±11.21 mmHg vs. 7.31±8.81 mmHg, p=0.146 (6 months); 6.05±11.14 mmHg vs. 6.61±10.64 mmHg, p=0.899 (24 months)). Percentage of diffusion capacity predicted (DLCO%) and percentage of total lung capacity predicted (TLC%), however, were significantly improved in the treatment group by the end of the study (P=0.010 and 0.027). St. George Respiratory questionnaire (SGRQ) scores were better after 6 months treatment with GM-CSF compared to the control group, and the benefits of treatment were maintained throughout the observation period. No severe side effects were observed during the study.

**Conclusion:** Six months of inhaled GM-CSF treatment had no effect on the alveolar–arterial oxygen gradient in patients with mild to moderate pulmonary alveolar proteinosis. There were changes in some clinical or laboratory measures, but no clinically important changes were noted at the end of study.

(Clinical Trial Registry: NCT02243228, Registered on September 17, 2014, https://www.clinicaltrials.gov/ct2/show/NCT02243228?term=NCT02243228&draw=2&rank=1)

**Background**

Autoimmune pulmonary alveolar proteinosis (aPAP, previously known as idiopathic PAP) is a rare interstitial lung disease elicited by the formation of autoantibodies which neutralize the activity of granulocyte-macrophage colony stimulating factor (GM-CSF), consequently decreasing macrophage clearance of surfactant [1]. Currently, the standard treatment strategy for PAP is whole lung lavage (WLL). About 70% patients need another WLL within 3 years due to recurrence [2, 3]. Patients who undergo WLL require general anesthesia and double-lumen endotracheal intubation, which means only hospitals with experienced physicians can perform the procedure. Considering the recurrence rate and the cumbersome procedure of WLL, whether or not patients with mild or moderate disease should obtain that treatment is a matter of controversy.

Inhaled GM-CSF therapy has become an attractive alternative option for aPAP patients not only due to its effectiveness and safety [4, 5], but also because it is a convenient treatment method for patients who are reluctant to receive WLL. Previous studies included small sample sizes, and as a result, disease severity has not been stratified. Nevertheless, whether patients with mild or moderate disease will benefit from GM-CSF treatment over the long term is still unclear. We prospectively evaluated if inhaled GM-CSF would delay disease progression in patients with mild to moderate aPAP over a two-year period.

**Methods**

**Participants**

Patients with mild or moderate aPAP aged between 18 and 80 years old, were enrolled at two hospitals, including Peking Union Medical College Hospital (PUMCH) and The Affiliated Drum Tower Hospital of Nanjing University Medical School in China.

The inclusion criteria included: (1) patients with a clinical diagnosis of PAP by high-resolution computed tomography (HRCT), further pathologically confirmed by testing for amorphous periodic Acid-Schiff (PAS)-positive granules; (2) a positive serum GM-CSF antibody test which indicated an elevated serum GM-CSF antibody level; and (3) patients eligible for the trial should have progressive or unremitting PAP, defined as worsening or unchanging PaO₂ or A-aDO₂ over a 3-month period of observation. PAS-positive granules were found either in milky broncho-alveolar lavage fluid (BALF) or in alveolar structures of lung biopsy tissues which were obtained as follows: cytological findings of bronchial lavage fluid only (BAL) (n=13), tranbronchial lung biopsy only (TBLB) (n=7), both TBLB and BAL (n=12), percutaneous lung puncture biopsy (n=3), and surgical lung biopsy only (n=1). The GM-CSF antibody test was performed according to the method established by Uchida et al [6, 7]. Our hospital set the cutoff point at 2.39g/mL, with measurements in excess of this value resulting a positive report [8].

Disease severity was assessed with a disease severity score (DSS), with patients with a DSS of 1 to 3 inclusive being included in our study. DSS scores were defined by Inoue et al. as follows [9]: Grade 1: No symptoms and an arterial oxygen partial pressure (PaO₂) ≥ 70mmHg; Grade 2: PaO₂ ≥ 70mmHg with symptoms; Grade 3: PaO₂ between 60-70mmHg; Grade 4: PaO₂ between 50-60mmHg; and Grade 5: PaO₂ below 50mmHg.

Individuals were excluded if they met the following criteria: (1) patients had already received previous GM-CSF therapy or other forms of cytokine therapy, or had undergone lung lavage therapy within the 3 months prior to enrollment; (2) Individuals with PAP resulting from other conditions (e.g. occupational exposure to silica, underlying human immunodeficiency virus infection, respiratory infections, myeloproliferative disorder or leukemia); (3) Individuals with histories of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies; (4) Individuals with chronic lung diseases or any other serious medical conditions, or (5) Women who were pregnant, lactating or planned to become pregnant during the study period.

**Study Design**

Autoimmune pulmonary alveolar proteinosis is a rare interstitial lung disease elicited by the formation of autoantibodies which neutralize the activity of granulocyte-macrophage colony stimulating factor, consequently decreasing macrophage clearance of surfactant. Currently, the standard treatment strategy for aPAP is whole lung lavage (WLL). About 70% of patients need another WLL within 3 years due to recurrence. Patients who undergo WLL require general anesthesia and double-lumen endotracheal intubation, which means only hospitals with experienced physicians can perform the procedure. Considering the recurrence rate and the cumbersome procedure of WLL, whether or not patients with mild or moderate disease should obtain that treatment is a matter of controversy.

Inhaled GM-CSF therapy has become an attractive alternative option for aPAP patients not only due to its effectiveness and safety, but also because it is a convenient treatment method for patients who are reluctant to receive WLL. Previous studies included small sample sizes, and as a result, disease severity has not been stratified. Nevertheless, whether patients with mild or moderate disease will benefit from GM-CSF treatment over the long term is still unclear. We prospectively evaluated if inhaled GM-CSF would delay disease progression in patients with mild to moderate aPAP over a two-year period.

Participants

Patients with mild or moderate aPAP aged between 18 and 80 years old, were enrolled at two hospitals, including Peking Union Medical College Hospital (PUMCH) and The Affiliated Drum Tower Hospital of Nanjing University Medical School in China.

The inclusion criteria included: (1) patients with a clinical diagnosis of PAP by high-resolution computed tomography (HRCT), further pathologically confirmed by testing for amorphous periodic Acid-Schiff (PAS)-positive granules; (2) a positive serum GM-CSF antibody test which indicated an elevated serum GM-CSF antibody level; and (3) patients eligible for the trial should have progressive or unremitting PAP, defined as worsening or unchanging PaO₂ or A-aDO₂ over a 3-month period of observation. PAS-positive granules were found either in milky broncho-alveolar lavage fluid (BALF) or in alveolar structures of lung biopsy tissues which were obtained as follows: cytological findings of bronchial lavage fluid only (BAL) (n=13), tranbronchial lung biopsy only (TBLB) (n=7), both TBLB and BAL (n=12), percutaneous lung puncture biopsy (n=3), and surgical lung biopsy only (n=1). The GM-CSF antibody test was performed according to the method established by Uchida et al [6, 7]. Our hospital set the cutoff point at 2.39g/mL, with measurements in excess of this value resulting a positive report [8].

Disease severity was assessed with a disease severity score (DSS), with patients with a DSS of 1 to 3 inclusive being included in our study. DSS scores were defined by Inoue et al. as follows [9]: Grade 1: No symptoms and an arterial oxygen partial pressure (PaO₂) ≥ 70mmHg; Grade 2: PaO₂ ≥ 70mmHg with symptoms; Grade 3: PaO₂ between 60-70mmHg; Grade 4: PaO₂ between 50-60mmHg; and Grade 5: PaO₂ below 50mmHg.

Individuals were excluded if they met the following criteria: (1) patients had already received previous GM-CSF therapy or other forms of cytokine therapy, or had undergone lung lavage therapy within the 3 months prior to enrollment; (2) Individuals with PAP resulting from other conditions (e.g. occupational exposure to silica, underlying human immunodeficiency virus infection, respiratory infections, myeloproliferative disorder or leukemia); (3) Individuals with histories of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies; (4) Individuals with chronic lung diseases or any other serious medical conditions, or (5) Women who were pregnant, lactating or planned to become pregnant during the study period.
This was a multicenter, randomized, open-label clinical trial (clinical trial number: NCT02243228, Inhalation of granulocyte-macrophage colony stimulating factor for autoimmune pulmonary alveolar proteinosis) comprising three sequential periods: high-dose therapy for 3 months, low-dose therapy for 3 months and observation for 18 months. Study visits during treatment were designed at 0, 1, 3 and 6 months. Thereafter, patients were followed up by visits at 9, 12, 15, 18, 21 and 24 months (Figure 1). Patients’ safety questionnaires were reviewed by telephone at 1, 15 and 21 months. Before the therapeutic trial, all participants entered an initial 3-month observation period, during which disease severity and progression were evaluated. Participants that had their PaO₂ increase by 10 mmHg or more, or alveolar-arterial oxygen gradient (A–aDO₂) decrease by 10 mmHg or more were regarded as having undergone spontaneous improvement and were excluded from enrollment. It should be noted that if a participant was acquainted to the principal investigator as a patient with a well-documented history showing an unremitting aPAP state, he/she could be enrolled into the study without this observation period. After 3-months of observation, all unremitting PAP patients underwent a stratified randomization based on their DSS at the time of enrollment to ensure equal representation of patients with various disease severities in both the treatment group and the placebo group using a random number table. The randomization was blinded to both the patients and the investigators.

Recombinant human GM-CSF (rhGM-CSF) was administered to patients in treatment group by inhalation as previously described [10]. 150 μg of rhGM-CSF was dissolved in 2 ml of sterile saline, and was inhaled as an aqueous aerosol using an LC-PLUS nebulizer with a manual interrupter valve connected to a PARI Turbo BOY compressor (PARI GmbH, Starnberg, Germany) [11]. Treatment was designed according to a previous study[12], including 3 months of high-dose GM-CSF administration (150 μg twice daily every other week) and another 3 months of low-dose administration (150 μg once daily every other week), serving as induction and maintenance therapy, respectively.

In the control group, patients were not prescribed any kind of treatment related to PAP (including GM-CSF, WLL or anti-CD20, etc.) but had the same follow up plan as the treatment group.

In previous published studies, patients inhaling GM-CSF had a mean change in A–aDO₂ of 11 mmHg [12]. Thus, the target sample size was 25, chosen to give a detection power of 90%, allowing for a 5% incidence of type-I error. After taking other outcome measurements and participant dropout into consideration, the study size was increased to 35-45 patients.

The study was approved by the institutional review board of PUMCH (Approval No. S-717) and reviewed by the institutional review boards at the Affiliated Drum Tower Hospital of Nanjing University Medical School. All participants provided informed written consent prior to enrollment.

Assessments

Clinical information including history, symptoms, serological (including lactate dehydrogenase, carcinoembryonic antigen levels) and radiological features, pulmonary function testing results and physical examination results were obtained at each visit during the study. Arterial blood gas analysis (ABG) tests were performed with patients that had been breathing room air for at least 15 minutes. A low dose quantitative computed tomography of the chest (in PUMCH) or high resolution CT (HRCT) of the chest (in The Affiliated Drum Tower Hospital of Nanjing University Medical School) was obtained before and after GM-CSF therapy and evaluated in a blinded fashion by a board-certified radiologist. The original CT measurements were collected, and the total lung volume and mean lung density were automatically calculated and post-processed with Pulmo 3D (syngo. via, version VA 30, Siemens Healthcare, Germany) for the automatic segmentation of the pulmonary parenchyma by excluding the intrapulmonary vessels following the process published by one of our co-authors, Dr. Sui [13].

Intergroup differences in the change of A–aDO₂ from baseline to the end of treatment were defined as primary endpoints.

Other data, representing the efficacy of GM-CSF inhalation, were also evaluated as secondary endpoints, including pulmonary function test differences between the treatment group and the control group (forced vital capacity [FVC], total lung capacity [TLC], diffusing capacity for carbon monoxide [DLCO] or diffusing capacity for carbon monoxide corrected for alveolar volume [DLCO/VA]), 6 minutes walking distance differences between the groups, and relapse time in the two groups. The definition of relapse was as follows: 1) a new requirement for whole lung lavage (WLL) or any other kind of treatment (including traditional medicine, subcutaneous injection or GM-CSF inhalation) due to disease progression; or 2) PAP death; or 3) reduction in PaO₂ of more than 10mmHg, or increase in A–aDO₂ of more than 10mmHg; or 4) a worsened chest HRCT independently confirmed by two physicians. Monitoring for adverse events was conducted during the study, looking for airway hypersensitivity, fever, myalgia, arrhythmia and potential effects on the circulatory system.

All blood tests were performed in laboratories affiliated with the two hospitals, both of which have China’s quality management certification. Serum levels of GM-CSF antibody were tested at PUMCH.

All of the data was collected and stored in the database system founded by Beijing Yikang Healthcare Technology Co.

Statistical analysis

All statistical analyses were performed using SPSS 20.0 software. Numeric results were presented as either the mean ± SD or the median and inter-quartile range. Metric variables were shown as the mean and categorical variables were given in terms of frequencies and percentages. The X² test was used to analyze proportions of variables. For group comparisons, the unpaired t tests and Wilcoxon rank-sum test were used to evaluate the differences in normally distributed variables. Kaplan-Meier Curve analysis was used to analyze time for relapse in the two groups. All P values reported were two-sided.

Results

Baseline demographic information
Forty-two aPAP patients were screened and 36 patients were randomized (19 in the treatment group and 17 in the control group). After 24 months of follow up, 26 patients (72.2%, 15 from the treatment group and 11 from the control group) completed the study. The period of recruitment and follow up was from July 20, 2014 to July 6, 2018 after the last enrolled patient completed his 24 months follow up. In the treatment group, one patient deteriorated at 3 months and required rescue therapy (WLL). Another patient lost follow up at 1 month and two more patients withdrew at 6 months. In the control group, 4 patients deteriorated at 3 months and required rescue therapy (one received GM-CSF inhalation, two received WLL and one was prescribed traditional medicine). 2 patients withdrew at 21 months. (Figure 2)

In 36 patients, the most common presenting symptom was dyspnea (20/36, 55.6%), followed by cough (13/36, 36.1%), phlegm (6/36, 16.7%) and chest pain (3/36, 8.3%). 4 out of our 36 patients were diagnosed by regular health check-up without any symptoms. The median duration of symptoms is 6 months (interquartile range is from 0 to 60 months) in our patients. All of our patients had extent bilateral pulmonary infiltrates confirmed by HRCT.

Demographic information of the 36 patients entered the study is shown in Table 1. There were no significant differences in demographic information between the treatment group and the control group including age and sex. No significant differences were found in patients’ disease severity markers at baseline, including symptoms, ABG, pulmonary function tests, 6 minutes walking distance (6MWD) and anti-GM-CSF antibody levels between the two groups.

Primary endpoint: A-aDO₂

There were no significant differences between the treatment group and control group based on primary endpoints measured by the change of A-aDO₂ from baseline to 3 and 6 months treatment and during the following 18 months [control group vs. treatment group: 0.51±12.09 mmHg vs. -0.35±13.76 mmHg, p=0.848 (at 3 months); 1.85±11.21 mmHg vs. 7.31±8.81 mmHg, p=0.146 (at 6 months); 6.05±11.14 mmHg vs. 6.61±10.64 mmHg, p=0.899 (at 24 months)] (Figure 3 A). The change of PaO₂ level from baseline to 3 and 6 months treatment, and during the following 18 months also showed no significant difference between the two groups (Figure 3 B). The actual level of A-aDO₂ and PaO₂ showed no differences during both the treatment period and follow up period as well (Figure 3 C and D) (Table 2 and 3).

The diffusion capacity and total lung capacity were improved by the end of study

Significant differences in DLCO% and TLC% between the control group and the control group emerged by the end of the study (Figure 4 A and B). [DLCO% (control group vs. treatment group): 67.12±14.72 vs. 69.19±19.83, p=0.732 (at 3 months); 70.83±14.62 vs. 74.91±14.80, p=0.465 (at 6 months); 64.67±16.22 vs. 80.87±19.40, p=0.027 (at 24 months)]; [TLC% (control group vs. treatment group): 74.09±11.37 vs. 73.12±15.29, p=0.836 (3 months); 74.28±11.18 vs. 78.48±8.88, p=0.269 (6 months); 70.97±10.79 vs. 79.77±7.76, p=0.010 (24 months)]. However, there were no significant differences between the treatment group and the control group in terms of other pulmonary function tests, including FVC, FEV₁ (data not shown) and DLCO/VA, both during the 6-month treatment period and the 18-month follow-up period. (Figure 4 C and D) (Table 2 and supplemental table 1)

The SGRQ scores increased after 3 months and 6 months of inhaled GM-CSF treatment and 18 months follow-up

Meanwhile, we can see obvious differences in patients’ quality of life between the treatment group and control group, as measured by SGRQ. Total SGRQ scores in patients in the treatment group was improved after 6 months of GM-CSF treatment compared to the no treatment group, and the benefits were nearly continuously maintained throughout the 18-month observation period. Similar trends can be observed in symptom score, activity score and effect score, although significant differences between the two groups were not observed at all times. (Figure 5)

Quantitative CT did not find difference after treatment

There were no significant differences in total lung volume and mean lung density between the treatment group and control group. (Table 2 and supplemental Table 1)

Time to rescue therapy during the 24-month study was not improved

There was no significant difference in time to rescue therapy between the treatment group and control group. Kaplan-Meier Curve analysis for the two groups was shown in Figure 6. (P=0.304)

Safety and tolerability of inhaled GM-CSF

None of our patients died during the trial. None of the patients in the treatment group complained of fever, wheezing or coughing over the duration of their inhaled GM-CSF treatment.

An increase in transaminase levels during GM-CSF inhalation treatment was observed (P=0.037). Fortunately, none of the patients required medical intervention. The highest observed level of transaminase in the GM-CSF treatment group was 123 U/L for glutamic-pyruvic transaminase (ALT) and 63 U/L for cereal grass transaminase (AST), while the highest observed level in the control group was 95 U/L for ALT and 77 U/L for AST respectively. All parameters remained stable or gradually declined after patients ceased alcohol consumption and stopped taking medicines with possible interfering effects. Peripheral blood neutrophils levels were not obviously increased within the GM-CSF inhalation group when compared to the control group (P=0.429). (Table 4)

No other significant safety and tolerability differences were observed between the two groups during the study.

Other details of side effects that occurred during the study can be found in the supplementary data.
Discussion

In this study, we prospectively evaluated the effects of inhaled GM-CSF on mild-to-moderate autoimmune pulmonary alveolar proteinosis (aPAP) patients. In contrast to previous reports, no obvious effects were found in our study. During the 6 months of treatment and 18 month of subsequent observation, the primary endpoint, A-aDO₂ remained unchanged. Health-related quality of life, measured using SGRQ improved after 3 months of treatment, with these improvements and maintained to 24 months. Marginal improvement was also noted in terms of TLC and DLCO by the end of the study. This research provides valuable clinical data and experience for inhaled GM-CSF treatment in aPAP patients who do not meet the criteria for WLL.

The current therapy for PAP patients involves the physical removal of surfactant using a procedure in which the lungs are repeatedly filled with saline and emptied – WLL – which is invasive, inefficient, and is not widely available. Some authors reported that fever, hypoxemia, fluid leakage and other complications occurred in patients treated with WLL [14]. Additionally, the median time to next WLL is around 15 months[15], and about 30%-57.6% of patients require further therapy after their first WLL [16, 17]. Though there is currently no consensus most physicians believe that patients with PaO₂ less than 70 mmHg when breathing room air or an alveolar-arterial [A-a] oxygen gradient of more than 40 mmHg, or patients with disease progression should receive WLL as treatment [14]. In a cohort study from our center, 33% of patients are stable or experience spontaneous remission [17], while the spontaneous remission rate varies from 8% to 18% in different reports [12, 15, 17, 18]. Considering the occurrence of spontaneous remission in some patients, it becomes a critical question whether GM-CSF inhalation could become a primary treatment for mild to moderate aPAP patients.

After GM-CSF was confirmed to play an important role in the disease mechanism of aPAP, the efficacy of exogenous GM-CSF replacement was assessed in a previous paper. The response rate to this treatment varied, with the efficacy rate being between 62% and 100% when using inhaled GM-CSF [5, 12, 19] while the efficacy rate was 43%–75% when using subcutaneously administered GM-CSF [20, 21]. Due to its better responsiveness and tolerance, the use of inhaled GM-CSF is generally recommended [4].

In previous studies, inhaled GM-CSF treatment was prescribed to patients with moderate to severe disease [10, 22-25], with the mean PaO₂ level in a large prospective study of inhaled GM-CSF treatment on aPAP patients being 61.7±1.4mmHg [12]. During the preparation of our manuscript, a randomized placebo-controlled study of inhaled GM-CSF was published, with A-aDO₂ and CT density quantitative measurement being significantly improved, though they concluded that clinical benefits were not significant [26]. There are two major differences in design between our study and Tazawa et al’s study as follows: (1) Tazawa et al recruited patients with PaO₂ of less than 70 mmHg (or less than 75 mmHg with symptoms), with the average PaO₂ being 66.4±8.66 mmHg and 68.8±8.96 mmHg in the GM-CSF group and control group respectively. Meanwhile, we recruited patients with a DSS of between 1 and 3 inclusive, 11/19 from our GM-CSF group and 13/17 from our control group had a PaO₂ of over 70mmHg, with an average PaO₂ of 77.51±8.53 mmHg in the GM-CSF group and 76.8±11.23 mmHg in the control group respectively. (2) While both trials used 6-months of treatment, Tazawa et al used 125 mg bid continuously, while we used 150 mg bid for 3 months and then 150 mg qd for 3 months. We found no significant response in the primary endpoint as measured by A-aDO₂. The reasons for the lack of response in our group may be related to the relatively good baseline oxygen content levels in our patients, making changes of this indicator less obvious. Based on our study and on previous papers, the benefits of GM-CSF treatment for aPAP patients with a PaO₂ of over 70/mmHg (DSS 1 and 2) may be very limited. There were not enough DSS3 cases (PaO₂ 60-70 mmHg) in our study for subgroup analysis. However, Tazawa, et al has answered this question with a randomized placebo-controlled study. We believe GM-CSF could be beneficial for those with a PaO₂ of less than 70mmHg. Additionally and critically, a significant difference in DLCO, which is a relatively reliable parameter to track improvement in aPAP patients, was observed after 24 months. This suggests that inhaled GM-CSF should be provided to patients in a personally-tailored manner, providing the drug for as long as is necessary for patients to respond to the drug [23, 27]. Longer treatment periods may be necessary for future clinical trials to confirm the efficacy of the inhaled GM-CSF in aPAP over the long term.

We found that inhaled GM-CSF therapy is a well-tolerated choice for aPAP patients as previous studies showed [10, 12, 22, 23]. Although more than half of our patients in the GM-CSF group were found to have slight increases in amino-transferase levels, and a number of abnormal liver function results were observed in the GM-CSF treatment group, the increases in transaminase levels were all slight and no medical intervention was needed for any of the patients. All patients remained in stable condition or gradually improved after the cessation of alcohol and stopping intake of possibly related combination medicines. Therefore, inhaled GM-CSF therapy is a safe and convenient choice for patients.

Our research has some limitations. Firstly, the sample size of the study was small, and there were not enough DSS3 patients for analysis. Our estimated target sample size was based on prior results, done using a patient population with greater disease severity [12], which may have caused an underestimation of the sample size actually needed. Secondly, more patients from the control group, compared to patients from the GM-CSF group, dropped out of the study during the observation period, which may have affected the effectiveness when comparing these two groups. Thirdly, the patients in our study did not receive a tailored dosage of GM-CSF treatment, nor did they receive prolonged therapy after the initial 6 months of treatment, which may have caused some latent responders, requiring higher dosages or longer treatment time for a positive response, to remain hidden.

Conclusions

Six months of inhaled GM-CSF treatment had no effects on the alveolar–arterial oxygen gradient in patients with mild to moderate pulmonary alveolar proteinosis. At the dosage we used, there were changes in some clinical or laboratory measures, but no clinically important changes were noted at the end of study. Our study is an important complement for efficacy in aPAP patients with mild to moderate disease severity.

List Of Abbreviations
Declarations

Ethics approval and consent to participate

The study was approved by the institutional review board of PUMCH (Approval No. S-717) and reviewed by the institutional review boards at the Affiliated Drum Tower Hospital of Nanjing University Medical School. All participants gave informed written consent prior to enrollment.

Consent for publication

Consent for publication was obtained from all participants.

Availability of data and materials

The data of our patients is available in the department of medical records at PUMCH and the Affiliated Drum Tower Hospital of Nanjing University Medical School. This data can be released with the agreement of the patients and is available from the corresponding author upon reasonable request.

Competing interests

This work was supported partly by the North China Pharmaceutical Corporation (NCPC) and Beijing Yikang Healthcare Technology Co. Ltd. Both companies were not involved in the data analysis and interpretation. The drug was donated by NCPC.

Funding information

The National Key Research and Development Program of China (2016YFC0901502), National Nature Science Foundation of China (81570061), the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (2017-12M-2-001, 2018-12M01-003).

Authors' contributions
XT and KFX designed, obtained consent, and drafted the manuscript; KFX and YX reviewed the eligibility of the patients’ enrollment. XT, YY, LC, WX, XL, JW, YZ, SM and YX followed up patients. XS and WS reviewed the CT scan and did quantity analysis of chest CT for the patients. YY, XG, WX collected data; XT, XG, XT and KFX designed, obtained consent, and drafted the manuscript; KFX and YX reviewed the eligibility of the patients’ enrollment. XT, YY, LC, WX, XL, JW, YZ, SM and YX drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Leilei Zhang for her help with the data entry.

References

1. Trapnell BC, Whitesitt JA, Nakata K. Pulmonary alveolar proteinosis. The New England journal of medicine 2003, 349(26):2527-2539.
2. Shende RP, Sampat BK, Prabhudesai P, Kulkarni SJ. Granulocyte macrophage colony stimulating factor therapy for pulmonary alveolar proteinosis. The Journal of the Association of Physicians of India 2013, 61(3):209-211.
3. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. American Journal of Respiratory & Critical Care Medicine 2008, 177(7):752-762.
4. Khan A, Agarwal R, Aggarwal AN. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis: a meta-analysis of observational studies. Chest 2012, 141(5):1273-1283.
5. Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, Okhouchi S, Tsuchihashi Y, Yokoba M, Eda R et al. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 2014, 145(4):729-737.
6. Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, Stevens C, Inoue Y, Yamada Y et al. Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods 2014, 402(1-2):57-70.
7. Uchida K, Nakata K, Trapnell BC, Terakawa T, Hamano E, Mikami A, Matsushita I, Seymour JF, Oh-Eda M, Ishige I et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004, 103(3):1089-1098.
8. Li Y, Tian X, Gui Y, Ma A, Li X, Zeng N, Zhang P, Li G, Xu K. [Serum markers in patients with idiopathic pulmonary alveolar proteinosis]. Zhonghua Jie He Hu Xi Za Zhi 2014, 37(7):497-501.
9. Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008, 177(7):752-762.
10. Tazawa R, Hamano E, Arai T, Ohta H, Ishimoto O, Uchida K, Watanabe M, Saito J, Takeshita M, Hirabayashi Y et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005, 171(10):1142-1149.
11. Coates AL, Dinh L, MacNeish CR, Rollin T, Gagnon S, Ho SL, Lands LC. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000, 13(3):169-178.
12. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuara H, Hizawa N, Kasahara Y, Tatsumi K, Hojo M et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010, 181(12):1345-1354.
13. Sui X, Du Q, Xu KF, Tian X, Song L, Wang X, Xu X, Wang Z, Wang Y, Gu J et al. Quantitative assessment of Pulmonary Alveolar Proteinosis (PAP) with ultra-dose CT and correlation with Pulmonary Function Tests (PFTs). PLoS One 2017, 12(3):e0172958.
14. Awab A, Khan MS, Youness HA: Whole lung lavage-technical details, challenges and management of complications. J Thorac Dis 2017, 9(6):1697-1706.
15. Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002, 166(2):215-235.
16. Gay P, Wallaert B, Nowak S, Yserbyt J, Anevlavis S, Hermant C, Lovis A, Menard O, Maitre B, Vandemoortele T et al. Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF. Respiration 2017, 93(3):198-206.
17. Zhao YY, Huang H, Liu YZ, Song XY, Li S, Xu ZJ: Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long-Term Follow-up Study. Chin Med J (Engl) 2015, 128(20):2714-2719.
18. Byun MK, Kim DS, Kim YW, Chung MR, Shim JJ, Cha SI, Uh ST, Park CS, Jeong SH, Park YB et al. Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population. J Korean Med Sci 2010, 25(3):393-398.
19. Papiris SA, Tsirigotis P, Koliakas L, Papadaki G, Papaoannou AI, Triantafillidou C, Papaportys K, Karakatsani A, Kagouridis K, Girosi M et al. Pulmonary alveolar proteinosis: time to shift? Expert Rev Respir Med 2015, 9(3):337-349.
20. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK: Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1143-1148.
21. Seymour JF, Presneill JJ, Schoch OD, Downie GH, Moore PE, Doyle IR, Vincent JM, Nakata K, Kitamura T, Langton D et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001, 163(2):524-531.
22. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM: Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006, 27(3):585-593.
23. Papiris SA, Tsirigotis P, Koliakas L, Papadaki G, Papaoannou AI, Triantafillidou C, Papaportys K, Karakatsani A, Kagouridis K, Girosi M et al. Long-term inhaled granulocyte-macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. Clin Drug Investig 2014, 34(8):553-564.
24. Ohkouchi S, Akasaka K, Ichiwata T, Hisata S, Iijima H, Takada T, Tsukada H, Nakayama H, Machiya JL, Irokawa T et al: Sequential Granulocyte-Macrophage Colony-Stimulating Factor Inhalation after Whole-Lung Lavage for Pulmonary Alveolar Proteinosis. A Report of Five Intractable Cases. 2017, 14(8):1298-1304.

25. Ding J, Xiao Y, Dai J, Miao L, Qiu Y, Chen L, Jiang H, Cai H: [Effectiveness and safety of inhaled granulocyte-macrophage colony-stimulating factor therapy in idiopathic pulmonary alveolar proteinosis]. Zhonghua Yi Xue Za Zhi 2015, 95(34):2766-2770.

26. Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A et al: Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. The New England journal of medicine 2019, 381(10):923-932.

27. Tazawa R, Kitamura N, Nakata K: Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. Reply. The New England journal of medicine 2020, 382(2):198.

Tables
Table 1
Demographic features of autoimmune pulmonary alveolar proteinosis (aPAP) patients at baseline.

| Parameter                          | Control group (n = 17) | Treatment group (n = 19) | P value |
|------------------------------------|------------------------|--------------------------|---------|
| Age (year)                         | 42.88 ± 12.75          | 43.53 ± 12.89            | 0.881   |
| Sex (female/male)                  | 4/13                   | 6/13                     | 0.717   |
| Duration of the disease (months)*  | 6 (6-60)               | 6 (0.5-60)               | 0.852   |
| Smoking status                     |                        |                          |         |
| Never                              | 7                      | 7                        | 0.965   |
| Ex-smoker                          | 5                      | 6                        |         |
| Current smoker                     | 5                      | 6                        |         |
| Disease Severity Score             |                        |                          | 0.409   |
| 1                                  | 0                      | 0                        |         |
| 2                                  | 13                     | 11                       |         |
| 3                                  | 4                      | 8                        |         |
| Hb (g/dL)                          | 16.11 ± 1.61           | 16.00 ± 1.64             | 0.839   |
| HCT (%)                            | 46.07 ± 3.7            | 45.74 ± 4.47             | 0.810   |
| LDH (U/L)                          | 244.06 ± 53.02         | 233.82 ± 43.43           | 0.547   |
| CEA (U/L)                          | 5.34 ± 4.96            | 4.74 ± 3.41              | 0.678   |
| FEV1 pred (%)                      | 78.09 ± 14.12          | 79.16 ± 15.68            | 0.832   |
| FVC pred (%)                       | 79.14 ± 13.42          | 79.71 ± 13.70            | 0.900   |
| TLC pred (%)                       | 74.59 ± 9.65           | 74.82 ± 10.78            | 0.946   |
| DLCO pred (%)                      | 69.50 ± 13.94          | 68.41 ± 16.90            | 0.835   |
| DLCO/VA pred (%)                   | 98.58 ± 18.45          | 98.67 ± 24.32            | 0.990   |
| PaO2 (mmHg)                        | 77.51 ± 8.53           | 76.88 ± 11.23            | 0.854   |
| A-aDO (mmHg)                       | 28.32 ± 9.09           | 28.74 ± 11.04            | 0.902   |
| SGRQ symptom                       | 24.06 ± 13.55          | 29.17 ± 29.75            | 0.506   |
| SGRQ activity                      | 30.70 ± 18.46          | 30.33 ± 16.55            | 0.949   |
| SGRQ effect                        | 24.20 ± 16.10          | 21.83 ± 21.29            | 0.712   |
| SGRQ total                         | 26.47 ± 14.74          | 27.38 ± 19.75            | 0.878   |
| 6MWD                               | 495.25 ± 79.39         | 477.95 ± 65.68           | 0.485   |
| SpO2 at the end of 6MWD            | 94.87 ± 2.70           | 94.58 ± 5.20             | 0.847   |
| Mean lung density                  | -718.62 ± 82.70        | -687.25 ± 68.48          | 0.315   |
| Total lung volume radiological measurement (ml) | 4556.08 ± 841.15       | 4461.08 ± 1399.60        | 0.841   |
| GM-CSF antibody (g/ml)             | 75.86 ± 93.94          | 73.30 ± 58.65            | 0.922   |

Abbreviations: aPAP: autoimmune pulmonary alveolar proteinosis; A-aDO2: alveolar arterial oxygen gradient; CEA: carcinoembryonic antigen; DLCO: DLCO: diffusing capacity for carbon monoxide; DLCO/VA: diffusing capacity for carbon monoxide corrected for alveolar volume; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; GM-CSF: granulocyte macrophage colony stimulating factor; Hb: hemoglobin; HCT: hematocrit; LDH: lactate dehydrogenase; PaO2: partial pressure of oxygen; SGRQ: St George Respiratory Questionnaire; SpO2: oxygen saturation in pulse oximetry; TLC: total lung capacity; 6MWD: 6 minutes walking distance (test).

*: median (inter-quartile range)

**: Traditional medicine treatment
|                      | 3 months Control group (n = 17) | Treatment group (n = 17) | Control group (n = 13) | Treatment group (n = 17) | P value | 6 months                      |
|----------------------|---------------------------------|--------------------------|------------------------|--------------------------|---------|-----------------------------|
| ΔA-aDO₂ (mmHg)       | 0.51 ± 12.09                    | -0.35 ± 13.76            | 1.85 ± 11.21           | 7.31 ± 8.81              | 0.848   | 1.85 ± 11.21                |
| A-aDO₂ (mmHg)        | 27.81 ± 11.04                   | 28.79 ± 10.19            | 25.69 ± 11.70          | 22.31 ± 7.45             | 0.794   | 25.69 ± 11.70               |
| ΔPaO₂ (mmHg)         | 0.92 ± 10.34                    | 0.62 ± 12.07             | 2.95 ± 10.34           | 7.26 ± 10.29             | 0.94    | 8.01 ± 16.50                |
| PaO₂ (mmHg)          | 78.42 ± 10.74                   | 78.37 ± 10.17            | 82.42 ± 9.71           | 83.84 ± 8.57             | 0.988   | 82.42 ± 9.71                |
| FVC pred (%)         | 77.24 ± 14.91                   | 78.48 ± 13.72            | 80.41 ± 15.60          | 77.34 ± 23.32            | 0.801   | 80.41 ± 15.60               |
| TLC pred (%)         | 74.09 ± 11.37                   | 73.12 ± 15.29            | 74.28 ± 11.18          | 78.48 ± 8.88             | 0.864   | 74.28 ± 11.18               |
| DLCO pred (%)        | 67.12 ± 14.72                   | 69.19 ± 19.83            | 70.83 ± 14.62          | 74.91 ± 14.80            | 0.732   | 70.83 ± 14.62               |
| DLCO/VA pred (%)     | 95.67 ± 17.32                   | 98.71 ± 21.03            | 98.92 ± 12.47          | 95.93 ± 15.44            | 0.641   | 98.92 ± 12.47               |
| SGRQ symptom         | 24.84 ± 17.33                   | 24.22 ± 23.32            | 29.50 ± 18.61          | 18.47 ± 19.29            | 0.521   | 29.50 ± 18.61               |
| SGRQ activity        | 33.45 ± 19.35                   | 24.31 ± 18.92            | 28.98 ± 18.78          | 19.41 ± 17.10            | 0.173   | 28.98 ± 18.78               |
| SGRQ effect          | 16.38 ± 15.94                   | 17.11 ± 17.86            | 21.58 ± 17.60          | 9.29 ± 10.73             | 0.336   | 21.58 ± 17.60               |
| SGRQ total           | 14.76 ± 14.52                   | 20.45 ± 17.55            | 25.11 ± 16.36          | 13.88 ± 10.91            | 0.285   | 25.11 ± 16.36               |
| 6MWD                 | 494.06 ± 75.43                  | 496.41 ± 75.43           | 475.09 ± 85.31         | 501.13 ± 88.31           | 0.926   | 475.09 ± 85.31              |
| Mean lung density    | NA                              | NA                       | -739.64 ± 82.70        | -733.17 ± 61.41          | 0.804   | -739.64 ± 82.70             |
| Total lung volume (ml)| NA                             | NA                       | 4485.71 ± 971.37      | 4365.67 ± 1322.58        | 0.808   | 4485.71 ± 971.37            |
| Hb (g/dL)            | 15.42 ± 1.53                    | 15.34 ± 1.42             | 15.65 ± 1.79           | 15.70 ± 1.60             | 0.863   | 15.65 ± 1.79                |
| HCT (%)              | 44.35 ± 3.54                    | 44.52 ± 3.48             | 45.10 ± 4.04           | 45.50 ± 4.46             | 0.881   | 45.10 ± 4.04                |
| LDH (U/L)            | 226.88 ± 46.22                  | 223.86 ± 59.32           | 230.36 ± 28.96         | 203.38 ± 60.36           | 0.867   | 230.36 ± 28.96              |
| CEA (U/L)            | 3.72 ± 3.31                     | 4.87 ± 3.68              | 4.40 ± 2.25            | 3.14 ± 1.74              | 0.619   | 4.40 ± 2.25                 |

Abbreviations: See Table 1.

Table 2
The clinical parameter of the effects of inhaled GM-CSF during the 6 months treatment periods.
Table 3
The primary end point results in the 18 months observational periods after 6 months inhaled GM-CSF treatment.

|                        | 9 months (n=12) | 12 months (n=13) | P value | 18 months (n=12) | P value | 24 months (n=11) | P value |
|------------------------|-----------------|------------------|---------|------------------|---------|------------------|---------|
| Δ A-aDO2 (mmHg)        | 4.53 ± 7.59     | 8.11 ± 10.89     | 0.461   | 5.19 ± 9.72      | 0.674   | 8.13 ± 15.02     | 0.579   |
| A-aDO2 (mmHg)          | 25.24 ± 7.05    | 22.16 ± 9.09     | 0.366   | 22.35 ± 6.54     | 0.756   | 18.38 ± 10.50    | 0.343   |
| Δ PaO2 (mmHg)          | 4.29 ± 8.38     | 7.45 ± 11.82     | 0.267   | 2.78 ± 11.41     | 0.496   | 8.13 ± 15.02     | 0.931   |
| PaO2 (mmHg)            | 81.08 ± 7.14    | 84.15 ± 8.93     | 0.362   | 81.84 ± 7.13     | 0.794   | 86.48 ± 10.75    | 0.721   |

Abbreviations: see Table 1.

Table 4
The side-effect of patients with aPAP during the GM-CSF treatment and follow up period.

|                  | Treatment periods | Follow up periods | P value |
|------------------|-------------------|-------------------|---------|
|                  | No treatment      | Treatment         |         |
|                  | group (n=17)      | group (n=19)      |         |
| Leukocytosis     | 1/17 (5.9%)       | 1/19 (5.3%)       | 1.0*    |
| Increase in      | 4/17 (23.5%)      | 11/19 (57.9%)     | 0.037   |
| aminotransferases|                   |                   |         |
| Increase in      | 6/17 (35.3%)      | 2/19 (10.5%)      | 0.167** |
| bilirubin        |                   |                   |         |

*: Fisher X2 test; **: continuous correction X2 test.

Table 4
The side-effect of patients with aPAP during the GM-CSF treatment and follow up period.

Figures
The clinical trial comprised of three sequential periods: high-dose therapy for 3 months (150 μg twice daily every other week), low-dose therapy for 3 months (150 μg once daily every other week) and observation for 18 months. Study visits during treatment were designed at 0, 3 and 6 months. Thereafter, patients were followed up with using visits at 9, 12, 18 and 24 months. Patients’ safety questionnaires were reviewed by telephone at 1, 15 and 21 months.
Figure 2

Flow diagram of the study cohort. aPAP: autoimmune pulmonary alveolar proteinosis; GM-CSF: granulocyte-macrophage colony stimulating factor.
No significant differences were observed between the treatment group and the control group in terms of changes in A-aDO2 and PaO2 from baseline to 3 and 6 months of treatment and over the following 18 months (A and B). [A-aDO2 levels in control group vs. treatment group: 0.51±12.09 mmHg vs. -0.35±13.76 mmHg, p=0.848 (at 3 months); 1.85±11.21 mmHg vs. 7.31±8.81 mmHg, p=0.146 (at 6 months); 6.05±11.14 mmHg vs. 6.61±10.64 mmHg, p=0.899 (at 24 months)]. No significant differences were observed between the treatment group and the control group for the absolute value of A-aDO2 and PaO2 during both the treatment period, as well as the follow up period (C and D).
There were significant differences in the DLCO% and TLC% between the treatment group compared to the control group at the end of the study (P<0.05, respectively, A and B). However, there were no significant differences between the two groups in terms of other pulmonary function tests, including FVC and DLCO/VA, both during the 6-month treatment period and the 18-month follow-up period (C and D). [DLCO% (control group vs. treatment group): 67.12±14.72 vs. 69.19±19.83, p=0.732 (at 3 months); 70.83±14.62 vs. 74.91±14.80, p=0.465 (at 6 months); 64.67±16.22 vs. 80.87±19.40, p=0.027 (at 24 months)]. [TLC% (control group vs. treatment group): 74.09±11.37 vs. 73.12±15.29, p=0.836 (at 3 months); 74.28±11.18 vs. 78.48±8.88, p=0.269 (at 6 months); 70.97±10.79 vs. 79.77±7.76, p=0.010 (at 24 months)].
Figure 5

The SGRQ score during the 24-month study period. A: total SGRQ score; B: SGRQ symptom score; C: SGRQ activity score; D: SGRQ effect score. *: P < 0.05, **: P < 0.01.
There was no significant difference between the treatment and control groups in terms of no disease progression rate (measured by time to rescue therapy) over the 24 month duration of the study. $P > 0.05$.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaldata2020525.docx